CN109562097B - 穿心莲内酯治疗多发性硬化的进行形式 - Google Patents

穿心莲内酯治疗多发性硬化的进行形式 Download PDF

Info

Publication number
CN109562097B
CN109562097B CN201780035899.2A CN201780035899A CN109562097B CN 109562097 B CN109562097 B CN 109562097B CN 201780035899 A CN201780035899 A CN 201780035899A CN 109562097 B CN109562097 B CN 109562097B
Authority
CN
China
Prior art keywords
multiple sclerosis
progressive
andrographolide
group
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780035899.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN109562097A (zh
Inventor
胡安·O·汉克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innobiosciences LLC
Original Assignee
Innobiosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innobiosciences LLC filed Critical Innobiosciences LLC
Publication of CN109562097A publication Critical patent/CN109562097A/zh
Application granted granted Critical
Publication of CN109562097B publication Critical patent/CN109562097B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780035899.2A 2016-06-08 2017-06-08 穿心莲内酯治疗多发性硬化的进行形式 Active CN109562097B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662347218P 2016-06-08 2016-06-08
US62/347,218 2016-06-08
PCT/US2017/036463 WO2017214346A1 (en) 2016-06-08 2017-06-08 Andrographolide treats progressive forms of multiple sclerosis

Publications (2)

Publication Number Publication Date
CN109562097A CN109562097A (zh) 2019-04-02
CN109562097B true CN109562097B (zh) 2022-06-07

Family

ID=60578163

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780035899.2A Active CN109562097B (zh) 2016-06-08 2017-06-08 穿心莲内酯治疗多发性硬化的进行形式

Country Status (8)

Country Link
US (1) US10722492B2 (https=)
EP (1) EP3468553B1 (https=)
JP (2) JP6928963B2 (https=)
CN (1) CN109562097B (https=)
CA (1) CA3026770C (https=)
DK (1) DK3468553T3 (https=)
MX (1) MX386393B (https=)
WO (1) WO2017214346A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019126759A1 (en) * 2017-12-22 2019-06-27 Convelo Therapeutics, Inc. Compounds and methods of promoting myelination
CN109293607A (zh) * 2018-11-14 2019-02-01 株洲千金药业股份有限公司 一种具有抗炎作用的化合物及其在制备抗炎药物中的应用
CN109223770A (zh) * 2018-11-14 2019-01-18 株洲千金药业股份有限公司 一种具有镇痛作用的化合物及其在制备镇痛药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1455826A2 (en) * 2001-12-21 2004-09-15 Ilex Oncology, Inc. Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment of multiple sclerosis
CN1921872A (zh) * 2004-02-03 2007-02-28 智利南方大学 用于激活PPR－γ受体而治疗自身免疫性疾病和阿尔茨海默病的提取自穿心莲的半日花烷型二萜类组合物
US9060994B2 (en) * 2011-12-21 2015-06-23 Inno Biosciences, S.p.A. Combination therapy with interferon and andrographolides for Multiple Sclerosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Carcamo, C等.ib-ms decreases disability progression in patients with progressive forms of multiple sclerosis. A double blind placebo controlled study.《MULTIPLE SCLEROSIS JOURNAL》.2016,第22卷第854页. *
ib-ms decreases disability progression in patients with progressive forms of multiple sclerosis. A double blind placebo controlled study;Carcamo, C等;《MULTIPLE SCLEROSIS JOURNAL》;20160930;第22卷;854 *
Treatment trials in progressive MS--current challenges and future directions;Marcus W Koch等;《Nat Rev Neurol》;20131231;第9卷(第9期);496-503 *

Also Published As

Publication number Publication date
EP3468553A1 (en) 2019-04-17
US20190083458A1 (en) 2019-03-21
JP2021165304A (ja) 2021-10-14
EP3468553A4 (en) 2020-02-12
CN109562097A (zh) 2019-04-02
JP2019517550A (ja) 2019-06-24
CA3026770A1 (en) 2017-12-14
DK3468553T3 (da) 2023-07-03
US10722492B2 (en) 2020-07-28
WO2017214346A1 (en) 2017-12-14
CA3026770C (en) 2024-05-28
MX386393B (es) 2025-03-18
JP6928963B2 (ja) 2021-09-01
EP3468553B1 (en) 2023-05-24
MX2018015208A (es) 2019-09-19

Similar Documents

Publication Publication Date Title
AU2017236177B2 (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
US10660872B2 (en) Methods for treatment of cognitive decline
CN104853755B (zh) 包含沃替西汀和多奈哌齐的组合物
US20230146896A1 (en) Composition and method for treating alzheimer's disease
CN117377476B (zh) 治疗与化学疗法诱发的周围神经病变相关的疼痛
CN109562097B (zh) 穿心莲内酯治疗多发性硬化的进行形式
ES3006014T3 (en) Use of nalfurafine for the treatment of demyelinating diseases
CN111973592A (zh) 治疗肌萎缩侧索硬化和神经病的方法
JP2024540439A (ja) 叢状神経線維腫の治療又は予防に使用するためのニトロキソリン
Sharma et al. Neuroprotective effects of berberine in Alzheimer's disease
AU2012359081B2 (en) Combination therapy with interferon and andrographolides for multiple sclerosis
WO2022052016A1 (en) Pharmaceutical compositions and uses thereof in treating parkinson's disease
CN120983423B (zh) 狭叶依瓦菊素在制备预防和/或治疗神经炎症的药物中的用途
US20090099102A1 (en) Ginkgolides in the Treatment and Prevention of Ovarian Cancer
CN112569237A (zh) 伊马替尼及其衍生物与尼古丁或其类似物联用或复方在防治尼古丁成瘾与复吸中的应用
RU2404976C1 (ru) Средство, снижающее влечение к алкоголизму, фармацевтическая композиция, способ ее получения, лекарственное средство и способ лечения
RU2805061C2 (ru) Лечение демиелинизирующих заболеваний
Balch et al. Appropriate Timing of Fluoxetine and Statin Delivery Reduces the Risk of Secondary Bleeding in Ischemic Stroke Rats
Zhong et al. Phosphodiesterase 4 as a therapeutic target in Parkinson's disease recent advances
TWI285108B (en) Therapeutic or preventive drug for osteoporosis comprising isotaxiresinol derived from Taxus yunnanensis
WO2015067216A1 (en) Novel use of a dimethyl sulphoxide (dmso) extract or fraction from graptopetalum sp.
HK40084518B (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound
HK40077546B (zh) 药学组合物及其於治疗帕金森氏症的用途
NZ625051B2 (en) Combination therapy with interferon and andrographolides for multiple sclerosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant